Search
for

    Sort by

    Community Join

    630-660 / 1000+ results

      community Kintor Phase 2 Results released KX-826 (pyrilutamide)

      in Research/Science  444 upvotes 3 years ago
      Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

      community Waiting to start treatment until Kintor KX-826 Phase 2 data is published?

      in Chat  17 upvotes 4 years ago
      People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.

      community Is Koshine (KX-826) worth the risk?

      in Treatment  5 upvotes 10 months ago
      OP is considering using KX-826 for hair loss due to side effects from other treatments like Minoxidil and finasteride. Users discuss the risks and safety of KX-826, with some suggesting caution due to its status as a research chemical.

      community Would you guys be interested in a pure cb-03-01 progress pick series?

      in Research  69 upvotes 6 years ago
      The conversation is about someone planning to use cb-03-01 for hair loss because they experience side effects with other treatments like finasteride, minoxidil, and RU58841. They have not found progress pictures online and are considering sharing their own experience with cb-03-01, which is expensive.

      community PP405 Phase 2a press release with early results

      in Research/Science  700 upvotes 1 year ago
      PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

      community Results of Procyanidin B2 in clinical studies

      in Treatment  13 upvotes 5 years ago
      Procyanidin B2, a compound derived from Annurca apples, as a potential treatment for pattern hair loss. Several clinical studies were mentioned, which found that procyanidin B2 could increase hair growth, density, and keratin content. Other treatments such as Minoxidil, Finasteride, and RU58841 were not discussed.

      community Any sources on Geranium sibiricum extract?

      in Product 4 years ago
      The conversation discusses the use of Minoxidil and finasteride for hair loss and explores the potential of Geranium sibiricum extract as a safer alternative. It highlights the difficulty in finding this specific extract and suggests considering other plants with similar compounds, like Indian gooseberry.

      community DNA Testing by Roots by Genetic Arts

      in Research/Science  4 upvotes 2 years ago
      A user shared their positive experience with Roots by GA, a company that creates personalized hair loss treatments based on DNA analysis, which confirmed their inability to tolerate finasteride. The user is satisfied with their progress 30 days after a hair transplant and the customized formula they received.

      community Dear RU58841 Users- How did it go?

      in Chat  4 upvotes 3 months ago
      RU58841 is used by some for hair loss when finasteride and minoxidil are ineffective. Users report mixed results, with some experiencing side effects like chest pain and mood changes.

      community Kintor long term safety phase 3

      in Research/Science  66 upvotes 1 year ago
      Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

      community Research behind RU-58642? Has anyone heard of this?

      in Research/Science  1 upvotes 1 year ago
      RU-58642 is a powerful anti-androgen that was not developed further, possibly due to safety concerns or financial reasons. RU58841 is a topical alternative, but it is less effective than finasteride and dutasteride, and its long-term effects are not well-studied.

      community An Uncontrolled Case Series Using a Botanically Derived, β-Cyclodextrin Inclusion Complex in Two Androgenetic Alopecia-Affected Male Subjects

      in Research/Science  1 upvotes 5 years ago
      The conversation discusses a botanically derived treatment for androgenetic alopecia using ingredients like saw palmetto, green tea, and evening primrose, showing impressive results over 270 days. Concerns include the study's uncontrolled nature and potential product motivation, with suggestions to enhance absorption through derma rolling.

      community Today I start with this: RU58841

      in Progress Pictures  31 upvotes 3 years ago
      The conversation is about a person starting treatment with RU58841 for hair loss. They are asked to share progress pictures to show if the treatment is effective.

      community HMI-115 when will it be available

      in Research/Science  15 upvotes 3 years ago
      The potential availability of a new hair loss treatment called HMI-115, which has shown promising results in experiments on monkeys but is not yet available to the public. Replies cautioned against using unproven substances from shady labs.

      community 2021 vs 2024. Consistency is key.

      in Progress Pictures  1910 upvotes 1 year ago
      The user shared progress pictures showing significant hair regrowth from using finasteride, RU58841, and liquid minoxidil, emphasizing the importance of consistency. They noted that RU58841, a research chemical not FDA-approved, was effective when applied topically but warned of potential heart-related side effects.

      community Any one here on GHK-RU58841? Does it work?

      in Product 1 year ago
      GHK-RU58841 is used for hair loss, with positive results when combined with finasteride, stemoxydine, redensyl, and alfatradiol. Users report effectiveness after adding finasteride.

      community Petition Alert: Let's Get PP405 Phase 3 Trials in Germany by 2026!

      in Research/Science  57 upvotes 11 months ago
      A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

      community Has anyone tried CB-01-03 aka Clascoterone?

      in Research/Science  2 upvotes 3 months ago
      Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.

      community Is pyri and gt20029 worth the hype????

      in Update  6 upvotes 2 years ago
      The conversation discusses the effectiveness of pyrithione zinc and GT20029 for hair loss. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

      community Don't use PP405 from everychem. it is likely fake.

      in Research/Science  66 upvotes 11 months ago
      PP405 from Everychem is likely fake and potentially harmful, with concerns about its stability and the risk of using the wrong MPC inhibitor, which could damage hair follicles. The real PP405 was studied under strict conditions, and DIY attempts are discouraged due to unknown formulation and quality control.

      community PP405 (Everychem 3HP) users - assemble and share your updates!!

      in Chat  44 upvotes 2 months ago
      Users discussed experiences with Everychem's solution similar to PP405 for hair loss, noting some positive results like increased hair thickness and new growth. There was skepticism about the product's legitimacy and safety, with some users reporting early signs of effectiveness and others expressing concerns about the lack of evidence and safety profiles.